Futura Medical PLC's (LON:FUM) CEO James Barder tells Proactive's Andrew Scott negotiations over a deal with a partner that would help commercialise their breakthrough erectile dysfunction treatment are at an advanced stage.
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren't appropriate or carry significant side-effects.
The update came a day after Futura announced interim data which indicated its lead drug can be administered in at least two higher-strength doses.
This has a knock-on positive impact for the imminent phase III clinical trial of MED2002, which is hoped will rubber stamp its huge potential.
Meet AusCann Group Holdings Ltd, Pacific American Coal Ltd, Kasbah Resources, Hazer Group Ltd and Kazia Therapeutics Ltd at our event,Sydney, 19 March 2018.Register here >>